A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.

@article{Lorenzo2004AFH,
  title={A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.},
  author={Cl{\'a}udia Maria de Lorenzo and Angela Arciello and Rosanna Cozzolino and Donald B. Palmer and Paolo Laccetti and Renata Piccoli and G D'alessio},
  journal={Cancer research},
  year={2004},
  volume={64 14},
  pages={4870-4}
}
We report the preparation and characterization of a novel, fully human antitumor immunoRNase (IR). The IR, a human RNase and fusion protein made up of a human single chain variable fragment (scFv), is directed to the ErbB-2 receptor and overexpressed in many carcinomas. The anti-ErbB-2 IR, named hERB-hRNase, retains the enzymatic activity of the wild-type enzyme (human pancreatic RNase) and specifically binds to ErbB-2-positive cells with the high affinity (K(d) = 4.5 nm) of the parental scFv… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Ribonucleases with Antiproliferative Properties : Molecular Biological and Biochemical Characteristics

С. Покровский, Е. М. Трещалина, +5 authors S. M. Deev
2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 34 references

A new human antitumor immunoreagent specific for ErbB2.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2002
View 9 Excerpts

Ligand-targeted therapeutics in anticancer therapy

Nature Reviews Cancer • 2002
View 1 Excerpt

Similar Papers

Loading similar papers…